Redeye updates Spago Nanomedical after reporting the Q1 result. During 2024, we look forward to the next update from the first stage of Tumorad’s open phase I/IIa study by mid-2024 and the result from SpagoPix partner discussion. Tumorad provides a significant upside potential, and SpagoPix can add support by securing access to growth capital. Our updated base case is SEK 1.0 (1.0), Bull case SEK 2.6 (2.6) and a Bear Case of SEK 0.2 (0.2).

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/